Bristol Myers Squibb's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Bristol Myers Squibb in the third quarter 2026?
Bristol myers Squibb Company achieved a return on average equity (ROE) of 43.83 % in its third quarter 2026, this is above BMY's average return on equity of 20.31%.
Bristol Myers Squibb Companys equity during the 12 months ending in the third quarter 2026 are valued at $21 billion

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 19 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 262, from total ROE ranking in the second quarter 2026 at 285.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	25.83 %	27.62 %	15.21 %	12.92 %	-
Y / Y Net Income Change	-1.5 %	152.55 %	8.77 %	1327.63 %	80.66 %
Net Income (TTM) in Millions	9,241	9,274	7,271	7,055	6,046
Return On Equity (TTM)	43.83 %	46.65 %	38.94 %	39.17 %	34.59 %
BMY's Total Ranking	# 262	# 285	# 306	# 367	# 332
Equity (TTM) in Millions	23,404	22,319	20,102	18,506	18,600
Seq. Equity Change	4.86 %	11.03 %	8.62 %	-0.51 %	6.35 %
Seq. Net Income Change	-34.8 %	23.82 %	146.82 %	-50.57 %	67.17 %

Back to BMY Management Effectiveness >> BMY's 5 Years Annual ROE >> Compare BMY ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 20
Sector	# 43
Overall	# 262

Return On Equity Statistics
High	Average	Low
74.74 %	20.31 %	-53.17 %
(Dec. 31, 2009)		(Dec 31 2024)

News about Bristol myers Squibb Company Return on Equity ROE

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-gener...

BioNTech and Bristol Myers Squibb Forge Strategic Alliance for Bispecific Antibody Development Amid Competitive Market Pressures MAINZ, Germany, and PRINCETON, USA June 2, 2025 In a significant move that underscores the dynamic landscape of oncology therapeutics, BioNTech (Nasdaq: BNTX) and Bristol Myers Squibb (NYSE: BMY) have announced a global strategic partnership aimed at co-developing and co-commercializing BioNTech s investigational bispecific antibody candidate, BNT327. This collaboration seeks to enhance the therapeutic options available for patients suffering from a range of solid tumor types.BNT327 represents a critical advancement in targeted therapies, utilizing bispecific antibody technology to engage two distinct targets simultaneously, thereby improving the precision and efficacy of cancer treatment. This innovative approach has the potential to revolutionize the current treatment paradigms for various malignancies, tapping into the promise of personalized medicine that is increasingly becoming a standard expectation in cancer care.

BMY Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	18,506	16,388	29,485	31,118	36,006
Y / Y Equity Change	12.92 %	-44.42 %	-5.25 %	-13.58 %	-4.95 %
Net Income in Millions	7,055	-8,933	8,040	6,345	7,014
Y / Y Net Income Change	-	-	26.71 %	-9.54 %	-
Return On Equity	38.12 %	-54.51 %	27.27 %	20.39 %	19.48 %

Back to BMY Management Effectiveness >> BMY's 5 Years Annual ROE >> Compare BMY ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 38.12 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BMY's' Return on Equity at Yahoo Finance
BMY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BMY's Competitors
Subscribers only: Roe for Bristol Myers Squibb's Suppliers
Subscribers only: Return On Equity for BMY's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Alector Inc	112.21 %
Medpace Holdings Inc	99.76 %
3m Company	93.07 %
Exelixis Inc	85.83 %
Amgen Inc	85.59 %
Eli Lilly And Company	83.65 %
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %

Date modified: 2026-10-30T16:58:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.